Boston Scientific Corporation filings document the regulatory record of a global medical technology company with device and therapy portfolios for cardiovascular, respiratory, digestive, oncological, neurological and urological conditions. Recent 8-K reports furnish operating results, clinical-trial announcements and other material events tied to products such as WATCHMAN and EKOS.
Proxy and governance filings cover director elections, executive compensation, stockholder votes, board committee matters and amendments to the company’s certificate of incorporation. Additional disclosures address capital resources and financing arrangements, including revolving credit terms, along with common-stock reporting, senior debt references, risk-related governance and formal exhibits filed under the Exchange Act.
BOSTON SCIENTIFIC CORP executive Emily Woodworth, SVP, Global Controller and CAO, reported a discretionary acquisition of 2,930 shares of common stock on 2026-08-11 at $51.19 per share. The shares were acquired indirectly through a rebalance in the company’s 401(k) Retirement Savings Plan, bringing her indirect 401(k) holdings to 2,930 shares.
A separate holding entry shows 3,123 shares held directly, which includes shares acquired under the Boston Scientific Employee Stock Purchase Plan based on the most current data available.
Boston Scientific EVP and CFO Jonathan Monson reported an indirect acquisition of 9,908 shares of Boston Scientific common stock on 2026-08-10 at $50.46 per share. The footnote states this was a discretionary rebalancing election under the company’s 401(k) Retirement Savings Plan, treated as a discretionary transaction under Rule 16b-3(f). After this transaction, he indirectly holds 9,908 shares through the 401(k) and separately reports 39,063 shares held directly.
Boston Scientific director David C. Habiger purchased 2,100 shares of common stock on August 5, 2026 in an open-market transaction at a weighted average price of $47.589 per share, with individual trade prices between $47.21 and $47.98. Following this purchase, he directly owns 17,160 shares.
FMR LLC and Abigail P. Johnson report beneficial ownership of Boston Scientific Corp common stock on a Schedule 13G/A. FMR LLC reports beneficial ownership of 46,378,258.61 shares, representing 3.1% of the outstanding common stock, as of June 30, 2026. FMR LLC has sole voting power over 39,968,563.03 shares and sole dispositive power over 46,378,258.61 shares, with no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over the same 46,378,258.61 shares, but no voting power. The filing notes that one or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the total outstanding common stock.
Boston Scientific Corp director David C. Habiger reported open-market purchases of Common Stock on two days in August 2026. He bought 1,042 shares on August 3 at a weighted average price of $48.0655 per share and 140 shares on August 4 at a weighted average price of $48.5879 per share. Each trade was executed through multiple transactions within stated price ranges, with detailed per-trade pricing available on request.
Boston Scientific CEO Michael F. Mahoney purchased 186,240 shares of common stock on August 3, 2026 at a weighted average price of $48.3323 per share, with individual trades between $47.87 and $48.47. After this open-market buy, he directly owns 1,590,024 shares and indirectly holds 22,119 shares via a 401(k) Retirement Savings Plan following a discretionary rebalancing transaction at $48.4300 per share.
Boston Scientific Corp director Edward J. Ludwig purchased 5,000 shares of common stock on July 31, 2026 at an average price of $45.4799 per share. After this open-market or private transaction, he directly owns 30,359 shares. The trade was not reported under a Rule 10b5-1 plan.
Boston Scientific Corp executive Joseph Michael Fitzgerald, EVP & Group President, Cardiology, reported a discretionary acquisition of 64,198 shares of common stock on 2026-07-31 through a rebalance of his holdings under the company’s 401(k) Retirement Savings Plan at $46.73 per share. These shares are held indirectly via the 401(k), which now reflects that balance. Separate entries show 213,907 shares held directly and 5,234 shares held by his child, with a footnote stating he disclaims beneficial ownership of the child’s shares.
Boston Scientific Corporation reported strong results for the quarter ended June 30, 2026, with net sales of $5.442 billion, up 7.5 percent on a reported basis and 7.0 percent on an operational and organic basis versus a year earlier. GAAP net income attributable to common stockholders was $907 million, or $0.61 per diluted share, compared with $797 million, or $0.53 per share. Adjusted EPS was $0.86, up from $0.75 and above the company’s guidance range of $0.82 to $0.84.
MedSurg net sales were $1.818 billion, up 5.9 percent reported, while Cardiovascular reached $3.624 billion, up 8.3 percent. Regional growth was 6.2 percent in the U.S., 11.2 percent in Asia-Pacific and 22.4 percent in Latin America and Canada on a reported basis.
The company completed a $2 billion accelerated share repurchase program, buying approximately 40 million shares, and invested $1.5 billion for an approximately 34 percent stake in MiRus LLC with an exclusive option on its TAVR business. For 2026, it projects reported net sales growth of 5.5 to 6.5 percent and adjusted EPS of $3.28 to $3.32, with third-quarter adjusted EPS expected at $0.80 to $0.82.